Phenoconversion transiently converts genotypic extensive metabolizers (EMs) into
phenotypic poor metabolizers (PMs) of drugs, potentially with corresponding changes in …

Introduction: Big-data-driven drug development resources and methodologies have been
evolving with ever-expanding data from large-scale biological experiments, clinical trials …

Drawing on insights from work in medical history and sociology, this book analyzes
changing meanings of personalized medicine over time, from the rise of biomedicine in the …

Considerable variety in how patients respond to treatments, driven by differences in their
geno-and/or phenotypes, calls for a more tailored approach. This is already happening, and …

Personalized medicine (PM) aims to harness a wave of 'omics' discoveries to facilitate
research and discovery of targeted diagnostics and therapies and increase the efficiency of …

Both inflammation and smoking can influence a drug's pharmacokinetic properties, ie, its
liberation, absorption, distribution, metabolism, and elimination. Depending on, eg …

Highlights•Recently developed small molecule-based, nanoparticle-based, and engineered
mammalian cell-based theranostic agents.•Comparison of each theranostic modality.•Future …

One of the basic questions in the early uses of pharmacogenetic (PGx) testing revolves
around the clinical delivery of testing. Because multiple health professionals may play a role …

Designing implantable bioelectronic systems that continuously monitor physiological
functions and simultaneously provide personalized therapeutic solutions for patients …

Clinical research faces a reproducibility crisis. Many recent clinical and preclinical studies
appear to be irreproducible-their results cannot be verified by outside researchers. This is …